ICD-10-CM Code C53.1

Malignant neoplasm of exocervix

Version 2020 Billable Code Diagnoses For Females Only Neoplasm Malignant Primary

Valid for Submission

C53.1 is a billable code used to specify a medical diagnosis of malignant neoplasm of exocervix. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C53.1 might also be used to specify conditions or terms like carcinoma of cervix or carcinoma of exocervix or malignant neoplasm of exocervix or neoplasm of exocervix or primary malignant neoplasm of exocervix.

The code C53.1 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.

The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: cervix (cervical) (uteri) (uterus) exocervix ; cervix (cervical) (uteri) (uterus) external os ; exocervix ; external os, cervix uteri ; os ; os external ; uterus, uteri, uterine exocervix ; etc

ICD-10:C53.1
Short Description:Malignant neoplasm of exocervix
Long Description:Malignant neoplasm of exocervix

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:

  • Diagnoses for females only - Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, this code applies to FEMALES only .

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Carcinoma of cervix
  • Carcinoma of exocervix
  • Malignant neoplasm of exocervix
  • Neoplasm of exocervix
  • Primary malignant neoplasm of exocervix

Diagnostic Related Groups

The ICD-10 code C53.1 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2020.

  • 736 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC
  • 737 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC
  • 738 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC
  • 739 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC
  • 740 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC
  • 741 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC

Convert C53.1 to ICD-9

  • 180.1 - Malig neo exocervix

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of female genital organs (C51-C58)
      • Malignant neoplasm of cervix uteri (C53)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Table of Neoplasms

The code C53.1 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»cervix (cervical) (uteri) (uterus)
  »exocervix
C53.1C79.82D06.1D26.0D39.0D49.59
»cervix (cervical) (uteri) (uterus)
  »external os
C53.1C79.82D06.1D26.0D39.0D49.59
»exocervix
C53.1C79.82D06.1D26.0D39.0D49.59
»external
  »os, cervix uteri
C53.1C79.82D06.1D26.0D39.0D49.59
»os
C53.1C79.82D06.1D26.0D39.0D49.59
»os
  »external
C53.1C79.82D06.1D26.0D39.0D49.59
»uterus, uteri, uterine
  »exocervix
C53.1C79.82D06.1D26.0D39.0D49.59
»uterus, uteri, uterine
  »external os
C53.1C79.82D06.1D26.0D39.0D49.59

Information for Patients


Cervical Cancer

The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection.

Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer.

Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday.

Vaccines can protect against several types of HPV, including some that can cause cancer.

NIH: National Cancer Institute


[Learn More]